Biogen Presents Update on its MS Therapeutic Portfolio
Biogen has released new data on several of its therapies for multiple sclerosis (MS), including Vumerity (diroximel…
Articles by Marisa Wexler, MS
Glatopa Shows Efficacy Similar to Copaxone, Study in Real-world Use Finds
Glatopa, a generic form of Copaxone, is as effective as the brand-name medication in terms of disease outcomes and…
Memory Immune Cells Play Key Role in Advanced MS, Study Suggests
In the brains of people with advanced multiple sclerosis (MS), memory immune cells reside in the brain tissue rather…
National MS Society Expert Panel Offers Guidelines for Regular Exercise
Healthcare providers should encourage everyone with multiple sclerosis (MS) to engage in regular exercise and keep physically active, new…
FDA Clears Nurocheck, Portable Device to Quickly Assess Brain Health
A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone…
Belong.Life Launches App to Support MS Patients and Healthcare Professionals
Belong.Life has launched a free and anonymous social network app to offer support for people…
Pain, Fatigue in MS and Neuromyelitis Optica Spectrum Compared in Study
Pain appears to be more intense in people with neuromyelitis optica spectrum disorder (NMOSD) than those with multiple…
Ublituximab Phase 2 Data Support Safety, Efficacy in Relapsing MS
The investigational anti-CD20 antibody ublituximab effectively depletes B-cells in people with relapsing forms of…
Ocrevus’ Early Use May Lower Need for Walking Aid by 49% Over 6 Years
Starting treatment with Ocrevus early can lower almost by half the need for a walking aid in people with relapsing forms…
XRHealth Raises $7M for Telehealth Expansion
XRHealth has raised $7 million to expand its telehealth platform, with the goal of providing clinicians and patients with…
Sanofi’s BTK Inhibitor Seen to Effectively Reduce Brain Lesions in Phase 2 Trial
The investigational, oral BTK inhibitor SAR442168 can limit the number of new inflammatory brain lesions in…
Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show
People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years…
Shorter Ocrevus Infusion Time Up for Approval in US and Europe
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from…
Sanofi to Detail Trial Results of Oral Relapsing MS Therapy Online on Thursday
Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety…
Gilenya May Raise Risk of Intestinal Parasitic Infection, Report Suggests
Treatment with Gilenya (fingolimod) could make people with multiple sclerosis (MS) more vulnerable to the parasitic infection known as…
New Database to Compile COVID-19 Data About People with MS and Related Diseases
The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have created a new database…
Study Finds Link Between Secondhand Smoke Exposure in Adolescence and MS Risk
People exposed to secondhand cigarette smoke during adolescence may be more likely to develop multiple sclerosis (MS) later in…
Headache a Common Side Effect of Interferon-beta Treatment, Study Finds
New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosis (MS)…
Regular Exercise ‘Strongly Recommended’ to Ease Fatigue in MS
Physical exercise can ease fatigue in people with multiple sclerosis (MS) and potentially benefit them in many other ways,…
Biosimilar Truxima Works as Well as Rituximab Originator in MS, Study Finds
Truxima, a biosimilar of rituximab, is comparable to the originator therapy in terms of effectiveness and safety for treating …
Canada Rules EHP-101, Potential Cannabidiol Treatment, Not Controlled Substance
EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health Pharmaceuticals (EHP) to treat multiple sclerosis (MS), is not a…
Janssen Seeks FDA Approval for Oral Ponesimod for Treating Relapsing MS
Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for…
Ponesimod, Up for Approval, Shows ‘Clear Superiority’ Over Aubagio, Janssen Exec Says
Ponesimod may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a…
Janssen Asks EMA to Approve Oral Ponesimod to Treat Relapsing MS
Janssen has submitted an application to the European Medicines Agency (EMA) asking that ponesimod be approved as…
Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active…
Number of People with MS in UK More Than Previously Estimated
New data from Public Health England (PHE) and the U.K. MS Society show that the number of people…
Cognitive Decline in MS May Not Be Inevitable or Progressive, 10-year Study Suggests
Progressive cognitive decline in patients with multiple sclerosis (MS) may not be as inevitable as previously thought, a study…
Mavenclad May Be Added to RRMS Treatments on Quebec’s Public Health Plan
The agency in charge of health and social services for Quebec, known as the Institut national d’excellence en santé et…
Mayzent Approved in Europe as First Oral Treatment for Active Secondary Progressive MS
The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant…
MSAA Marks 50th Anniversary with Benefit Evening, New Logo and More
The Multiple Sclerosis Association of America (MSAA) is celebrating 50 years of work and dedication to improving the lives…